Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human

Journal of Pharmacological and Toxicological Methods

Volumn 68, Issue 3, 2013, Pages 357-366

  Parkinson, Joanna ^a,b   Visser, Sandra A G ^c   Jarvis, Philip ^a   Pollard, Chris ^a   Valentin, Jean Pierre ^a   Yates, James W T ^a   Ewart, Lorna ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Dofetilide; Dog; Methods; Moxifloxacin; PKPD; QT interval; Translation

Indexed keywords

ANTIARRHYTHMIC AGENT; AZD 1305; AZD 1386; DOFETILIDE; MOXIFLOXACIN; PLACEBO; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL MODEL; CARDIOVASCULAR EFFECT; CASE STUDY; CHILD; CONSCIOUSNESS; CONTROLLED STUDY; DELTA RHYTHM; DOG; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HUMAN EXPERIMENT; MALE; NONHUMAN; NORMAL HUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; QT INTERVAL; QT PROLONGATION; QT SHORTENING; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TELEMETRY; TRANSLATIONAL RESEARCH; VOLUNTEER;

CANIS FAMILIARIS;

DOFETILIDE; DOG; METHODS; MOXIFLOXACIN; PKPD; QT INTERVAL; TRANSLATION;

ADULT; ANIMALS; AZA COMPOUNDS; AZABICYCLO COMPOUNDS; BENZIMIDAZOLES; CARBAMATES; CLINICAL TRIALS, PHASE I AS TOPIC; DOGS; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHENETHYLAMINES; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SPECIES SPECIFICITY; SULFONAMIDES; TELEMETRY; TRANSLATIONAL MEDICAL RESEARCH; YOUNG ADULT;

EID: 84886398651     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.03.007     Document Type: Article

References (47)

1. Abel S., Nichols D.J., Brearley C.J., Eve M.D. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. British Journal of Clinical Pharmacology 2000, 49(1):64-71.
2. Alexandrou A.J., Duncan R.S., Sullivan A., Hancox J.C., Leishman D.J., Witchel H.J., et al. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. British Journal of Pharmacology 2006, 147(8):905-916. 10.1038/sj.bjp.0706678.
3. Anon ICH S7B: The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002841.pdf.
4. Anon International conference on harmonisation - ICH E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf.
5. Antzelevitch C., Pollevick G.D., Cordeiro J.M., Casis O., Sanguinetti M.C., Aizawa Y., et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007, 115(4):442-449. 10.1161/CIRCULATIONAHA.106.668392.
6. Bazett H.C. The Q-T intervals. Heart 1920, 7:353.
7. Bril A., Gout B., Bonhomme M., Landais L., Faivre J.F., Linee P., et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: Experimental profile of BRL-32872. Journal of Pharmacology and Experimental Therapeutics 1996, 276(2):637-646.
8. Brown A.M. Drugs, hERG and sudden death. Cell Calcium 2004, 35(6):543-547. 10.1016/j.ceca.2004.01.008.
9. Carlsson L., Andersson B., Linhardt G., Löfberg L. Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo. Journal of Cardiovascular Pharmacology 2009, 54:82-89.
10. Champeroux P., Ouillé A., Martel E., Fowler J.S.L., Maurin A., Richard S., et al. A step towards characterisation of electrophysiological profile of torsadogenic drugs. Journal of Pharmacological and Toxicological Methods 2011, 63(3):269-278. 10.1016/j.vascn.2011.01.001.
11. Christensen T.F., Randløv J., Kristensen L.E., Eldrup E., Hejlesen O.K., Struijk J.J. QT measurement and heart rate correction during hypoglycemia: Is there a bias?. Cardiology Research and Practice 2010, 961290.
12. Curran M.E., Splawski I., Timothy K.W., Vincen G.M., Green E.D., Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80(5):795-803. 10.1016/0092-8674(95)90358-5.
13. Danhof M., de Lange E.C.M., Della Pasqua O.E., Ploeger B.A., Voskuyl R.A. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends in Pharmacological Sciences 2008, 29(4):186-191. 10.1016/j.tips.2008.01.007.
14. Applied regression analysis 1981, John Wiley & Sons, (ISBN 0-471-029995-5). 2nd ed. N.R. Draper, H. Smith (Eds.).
15. Dubois V.F.S., Chain A., van de Graaf P., Leishman D., Gallacher D., McMahon N., et al. Interspecies comparison of moxifloxacin induced QTc-interval prolongation. Population Approach Group in Europe (PAGE) Meeting 2011.
16. Fermini B., Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Reviews. Drug Discovery 2003, 2:439-447.
17. Fridericia L.S. Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Medica Scandinavica 1920, 53(1):469-486. 10.1111/j.0954-6820.1920.tb18266.x.
18. Groth A.V. Alternative parameterisations of saturable (emax) models allowing for nesting of non-saturable models [Abstract]. PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe, Abstr 1371 2008.
19. Hammond T.G., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Redfern W.S., et al. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey. Cardiovascular Research 2001, 49(4):741-750. 10.1016/S0008-6363(00)00310-2.
20. Holbrook M., Malik M., Shah R.R., Valentin J. Drug induced shortening of the QT/QTc interval: An emerging safety issue warranting further modelling and evaluation in drug research and development?. Journal of Pharmacological and Toxicological Methods 2009, 59(1):21-28. 10.1016/j.vascn.2008.09.001.
21. Jonker D.M., Kenna L.A., Leishman D., Wallis R., Milligan P.A., Jonsson E.N. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clinical Pharmacology and Therapeutics 2005, 77:572-582.
22. Jonsson E.N., Karlsson M.O. Xpose-An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Computer Methods and Programs in Biomedicine 1998, 58(1):51-64. 10.1016/S0169-2607(98)00067-4.
23. Karlsten R., Jonzon B., Quiding H., Carlsson M.A., Segerdahl M., Malamut R., et al. The TRPV1 antagonist AZD1386 inhibits capsaicin and heat evoked pain in healthy volunteers. International Association for the Study of Pain (IASP), 13th World Congress on Pain. Presentation Number: PM 380 2010.
24. Laird J.M., Martino G., Visser S., Oerther S., Yu X.H., Perkins N. The novel TRPV1 antagonist, AZD1386, produces plasma concentration-dependent reversal of heat hyperalgesia in inflammatory and neuropathic rat pain models in the absence of hyperthermic effects. International Association for the Study of Pain (IASP), 13th World Congress on Pain. Presentation Number: PH 379 2010.
25. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. Journal of Cardiovascular Pharmacology 2004, 43(3):369-379.
26. Molnar J., Zhang F., Weiss J., Ehlert F.A., Rosenthal J.E. Diurnal pattern of QTc interval: How long is prolonged?: Possible relation to circadian triggers of cardiovascular events. Journal of the American College of Cardiology 1996, 27(1):76-83. 10.1016/0735-1097(95)00426-2.
27. Moss A.J. The QT interval and torsade de pointes. Drug Safety 1999, 21:5-10.
28. Nagy D., DeMeersman R., Gallagher D., Pietrobelli A., Zion A.S., Daly D., et al. QTc interval (cardiac repolarization): Lengthening after meals. Obesity Research 1997, 5:531-537.
29. Ollerstam A., Persson A.H., Visser S.A., Fredriksson J.M., Forsberg T., Nilsson L.B., et al. A novel approach to data processing of the QT interval response in the conscious telemetered beagle dog. Journal of Pharmacological and Toxicological Methods 2007, 55(1):35-48. 10.1016/j.vascn.2006.02.009.
30. Ollerstam A., Visser S.A., Duker G., Forsberg T., Persson A.H., Nilsson L.B., et al. Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. Journal of Pharmacological and Toxicological Methods 2007, 56(2):131-144. 10.1016/j.vascn.2007.05.002.
31. Ollerstam A., Visser S.A., Persson A.H., Eklund G., Nilsson L.B., Forsberg T., et al. Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs. Journal of Pharmacological and Toxicological Methods 2006, 53(2):174-183. 10.1016/j.vascn.2005.07.002.
32. Othman A.A., Nothaft W., Awni W.M., Dutta S. Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: Pharmacokinetic/Pharmacodynamic analysis of three phase 1 trials. British Journal of Clinical Pharmacology 2012, 10.1111/j.1365-2125.2012.04405.x.
33. Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS 2005, 24:609-624.
34. Prior H., McMahon N., Schofield J., Valentin J. Non-invasive telemetric electrocardiogram assessment in conscious beagle dogs. Journal of Pharmacological and Toxicological Methods 2009, 60(2):167-173. 10.1016/j.vascn.2009.06.001.
35. R Development Core Team R: A language and environment for statistic computing 2008, R Foundation for Statistical Computing, Vienna, Austria.
36. Rónaszéki A., Alings M., Egstrup K., Gaciong Z., Hranai M., Király C., et al. Pharmacological cardioversion of atrial fibrillation-A double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously. Europace 2011, 13(8):1148-1156. 10.1093/europace/eur120.
37. Sanguinetti M.C., Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440:463-469.
38. Schoemaker R.C., Cohen A.F. Estimating impossible curves using NONMEM. British Journal of Clinical Pharmacology 1996, 42(3):283-290. 10.1046/j.1365-2125.1996.04231.x.
39. Shah R.R. The significance of QT interval in drug development. British Journal of Clinical Pharmacology 2002, 54(2):188-202. 10.1046/j.1365-2125.2002.01627.x.
40. Shah R.R. Drug-induced QT interval shortening: Potential harbinger of proarrhythmia and regulatory perspectives. British Journal of Pharmacology 2010, 159(1):58-69. 10.1111/j.1476-5381.2009.00191.x.
41. Sheiner L.B., Stanski D.R., Vozeh S., Miller R.D., Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clinical Pharmacology and Therapeutics 1979, 25:358-371.
42. Siefert H.M., Domdey-Bette A., Henninger K., Hucke F., Kohlsdorfer C., Stass H.H. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: A comparison in humans and other mammalian species. Journal of Antimicrobial Chemotherapy 1999, 43(suppl 2):69-76. 10.1093/jac/43.suppl_2.69.
43. Smith D.A., Rasmussen H.S., Stopher D.A., Walker D.K. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 1992, 22(6):709-719. 10.3109/00498259209053133.
44. Stass H., Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. Journal of Antimicrobial Chemotherapy 1999, 43(Suppl. 2):83-90. 10.1093/jac/43.suppl_2.83.
45. Van de Water A., Verheyen J., Xhonneux R., Reneman R.S. An improved method to correct the Q-T interval of the electrocardiogram for changes in heart rate. Journal of Pharmacological Methods 1989, 22:207-217.
46. Watson K.J., Gorczyca W.P., Umland J., Zhang Y., Chen X., Sun S.Z., et al. Pharmacokinetic-pharmacodynamic modelling of the effect of moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods 2011, 63(3):304-313. 10.1016/j.vascn.2011.03.002.
47. Weerapura M., Hébert T.E., Nattel S. Dofetilide block involves interactions with open and inactivated states of HERG channels. European Journal of Physiology 2002, 443:520-531.